Abliva AB (ABLI)

Stockholm
0.42
+0.01(+3.28%)
  • Volume:
    296,198
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    0.41 - 0.43
  • Type:Equity
  • Market:Sweden
  • ISIN:SE0002575340
  • S/N:403006798

ABLI Overview

Prev. Close
0.41
Day's Range
0.41-0.43
Revenue
160K
Open
0.42
52 wk Range
0.36-0.77
EPS
-0.33
Volume
296,198
Market Cap
169.26M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
481,523
P/E Ratio
-
Beta
1.13
1-Year Change
-41.6%
Shares Outstanding
403,006,798
Next Earnings Date
26 May 2022
What is your sentiment on Abliva AB?
or
Market is currently closed. Voting is open during market hours.

Abliva AB Company Profile

Abliva AB Company Profile

Employees
9
Market
Sweden

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children’s Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellNeutralBuyStrong Sell
Technical IndicatorsNeutralNeutralNeutralStrong BuyStrong Sell
SummarySellSellNeutralStrong BuyStrong Sell